LIVMARLI cuts bile acids 70% in Phase 3. Can Mirum turn its biliary atresia breakthrough into FDA approval?
Mirum's LIVMARLI meets its Phase 3 itch endpoint and cuts bile acids, supporting a planned 2027 FDA filing for rare liver diseases.
Pharma & Biotech
Pharma & Biotech
GLP-1 prescribing rises 310-fold among U.S. children aged 8–11 with obesity
An NYU Langone study of more than 3.5 million children found rapidly increasing off-label GLP-1 prescribing below age 12, concentrated among children with severe obesity and related disease.